As of June 8, 2025, Jounce Therapeutics Inc (JNCE) reports a ROE (Return on Equity) of -27.81%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Jounce Therapeutics Inc's ROE (Return on Equity)
Over recent years, Jounce Therapeutics Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | -27.81% |
| 2021-12-31 | -40.60% |
| 2020-12-31 | -20.73% |
| 2019-12-31 | 32.53% |
| 2018-12-31 | -26.32% |
This slight upward trend highlights how Jounce Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Jounce Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Jounce Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Jounce Therapeutics Inc (JNCE) | -27.81% |
| Rigel Pharmaceuticals Inc (RIGL) | 531.78% |
| Abbvie Inc (ABBV) | 128.66% |
| Agenus Inc (AGEN) | 69.62% |
| Amgen Inc (AMGN) | 69.59% |
| Selecta Biosciences Inc (SELB) | 37.71% |
Compared to its competitors, Jounce Therapeutics Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.